The market capitalisation of Australian company Neuren Pharmaceuticals has surged 20 per cent to almost $1 billion after it announced that the US FDA has approved its treatment for Rett syndrome. …
Australian company surges on FDA approval of innovative therapy
March 13, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Radiopharm Theranostics reports Preclinical Lu177-B7H3-mAb data
June 2, 2025 - - Australian Biotech -
Neurotech announces positive human PK study results for NTI164
June 2, 2025 - - Australian Biotech -
Cardiex receives TGA approval for CONNEQT Pulse arterial health monitor
June 2, 2025 - - Australian Biotech -
Pharmac minister sworn in as New Zealand's Deputy Prime Minister
June 1, 2025 - - Latest News -
An opportunity for reflection on the need to humanise PBS decision-making
June 1, 2025 - - Latest News -
Ipsen's Julien Dagher promoted to European leadership role
June 1, 2025 - - Latest News -
Daiichi Sankyo secures certification as Great Place to Work
June 1, 2025 - - Latest News